Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

850P - Acute lymphoblastic leukemia patients receiving prophylactic cranial irradiation by volumetric modulated ARC therapy with hippocampal sparing: Dosimetric analysis

Date

16 Sep 2021

Session

ePoster Display

Topics

Radiation Oncology

Tumour Site

Leukaemias

Presenters

Ambedkar Yadala

Citation

Annals of Oncology (2021) 32 (suppl_5): S773-S785. 10.1016/annonc/annonc676

Authors

A. Yadala, A. Mukerjhi, N. VIJAYAPRABHU, E. Thiravayam, S. shivakumar, K. azhivahgan

Author affiliations

  • Radiation Oncology Dept, JIPMER, 605006 - PUDUCHERRY/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 850P

Background

Acute lymphoblastic leukemia is one among the common paediatric malignancies. CNS relapse is the major concern in treatment of ALL because of inability of chemotherapy to cross the blood-brain barrier. CNS directed treatments include prophylactic cranial irradiation (PCI), intrathecal methotrexate (ITMTX) and high dose systemic therapy. A combination of PCI and IT MTX is the most commonly used CNS directed therapy. PCI is associated with neurocognitive side effects, memory and attention deficits. Radiation induced hippocampal damage is one of the causes for the side effects. The purpose of this to deliver PCI with hippocampal sparing using VMAT and also do a dosimetric analysis of the dose volume data generated.

Methods

25 patients were treated with hippocampal sparing PCI using VMAT. Dose of PCI was used according to the treatment protocol of the patient.18Gy and 12Gy dose schedules were used for most of the patients.

Results

For patients treated with 18Gy the mean dose to PTV was 18.9 Gy ± 0.3 Gy and hippocampus received a mean dose of 8.9 Gy ± 0.3 Gy. Conformity index and homogeneity index were 0.9 and 0.1 respectively. For patients treated with 12Gy the mean dose to PTV was 13.3 Gy ± 0.3 Gy and hippocampus received a mean dose of 7Gy ± 1 Gy. Conformity index and homogeneity index were 0.9 and 0.1 respectively.

Conclusions

Our study showed that PCI with hippocampal sparing through VMAT can achieve 100% dose coverage to PTV while keeping the dose to hippocampus to less than 9Gy which is less than the threshold dose causing neurocognitive effects. By achieving this low dose to the hippocampus, there is possibility avoid neurocognitive side effects in lonterm survivors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

JIPMER.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.